1. Mutations in Bone Marrow-Derived Stromal Stem Cells Unmask Latent Malignancy
- Author
-
Christine Hewes, Theofilos Poutahidis, Glennice N. Bowen, Yingwang Liu, Jian Hua Liu, Hanchen Li, Anna M. Cerny, Stephen Lyle, Varada P. Rao, Nathan F. Moore, Xueli Fan, Susan E. Erdman, JeanMarie Houghton, Christine L. Taylor, Jan Cerny, Evelyn A. Kurt-Jones, and Erin A. Jackson
- Subjects
Mice, SCID ,Gene mutation ,medicine.disease_cause ,T-Lymphocytes, Regulatory ,Epithelium ,Mice ,Original Research Reports ,Bone Marrow ,Cell Movement ,Mice, Inbred NOD ,Aged, 80 and over ,Mice, Knockout ,Mutation ,Carcinoma, Ductal, Breast ,Hematology ,Middle Aged ,DNA-Binding Proteins ,medicine.anatomical_structure ,Female ,Tumor necrosis factor alpha ,Stem cell ,Adult ,Genes, APC ,Stromal cell ,Transplantation, Heterologous ,Mutation, Missense ,Bone Marrow Cells ,Breast Neoplasms ,Mammary Neoplasms, Animal ,Biology ,Mesenchymal Stem Cell Transplantation ,Mammary Glands, Animal ,Immune system ,Antigens, CD ,Cell Line, Tumor ,medicine ,Animals ,Humans ,Aged ,Cell Proliferation ,Tumor Necrosis Factor-alpha ,Mesenchymal stem cell ,Mesenchymal Stem Cells ,Cell Biology ,Fibroblasts ,Mice, Mutant Strains ,Mice, Inbred C57BL ,Culture Media, Conditioned ,Immunology ,Cancer research ,Bone marrow ,Stromal Cells ,Tumor Suppressor Protein p53 ,Neoplasm Transplantation ,Developmental Biology - Abstract
Neoplastic epithelia may remain dormant and clinically unapparent in human patients for decades. Multiple risk factors including mutations in tumor cells or the stromal cells may affect the switch from dormancy to malignancy. Gene mutations, including p53 mutations, within the stroma of tumors are associated with a worse clinical prognosis; however, it is not known if these stromal mutations can promote tumors in genetically at-risk tissue. To address this question, Apc(Min/+) and Apc(Min/+) Rag2(-/-) mice, which have a predilection to mammary carcinoma (as well as wild-type (wt) mice), received mesenchymal stem cells (MSC) with mutant p53 (p53MSC) transferred via tail vein injection. In the wt mouse, p53MSC circulated in the periphery and homed to the marrow cavity where they could be recovered up to a year later without apparent effect on the health of the mouse. No mammary tumors were found. However, in mice carrying the Apc(Min/+) mutation, p53MSC homed to mammary tissue and significantly increased the incidence of mammary carcinoma. Tumor necrosis factor (TNF)-alpha-dependent factors elaborated from mesenchymal cells converted quiescent epithelia into clinically apparent disease. The increased cancer phenotype was completely preventable with neutralization of TNF-alpha or by transfer of CD4(+) regulatory T cells from immune competent donors, demonstrating that immune competency to regulate inflammation was sufficient to maintain neoplastic dormancy even in the presence of oncogenic epithelial and stromal mutations. The significant synergy between host immunity and mesenchymal cells identified here may restructure treatments to restore an anticancer microenvironment.
- Published
- 2010
- Full Text
- View/download PDF